TrialRMD open2024
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
Roy Fleischmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled ittrialcites it